Gene Delivery Using Viral Vectors - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 259

[38] Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenovi-
ral vector: replacement of all viral coding sequences with 28 kb of DNA independently
expressing both full-length dystrophin and b-galactosidase. Proc Natl Acad Sci U.S.A.
1996;93:5731-6.
[39] Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent
adenovirus vector system: removal of helper virus by cre-mediated excision of the viral
packaging signal. Proc Natl Acad Sci U.S.A. 1996;93:13565-70.
[40] Zhou H, Zhao T, Pastore L, Nageh M, Zheng W, Rao XM, et al. A Cre-expressing cell
line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus
vector. Mol Ther 2001;3:613-22.
[41] Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW. Adenovirus-mediated
regulable target gene expression in vivo . Proc Natl Acad Sci U.S.A. 1999;96:355-60.
[42] Nomura S, Merched A, Nour E, Dieker C, Oka K, Chan L. Low-density lipoprotein receptor
gene therapy using helperdependent adenovirus produces long-term protection against athero-
sclerosis in a mouse model of familial hypercholesterolemia. Gene Ther 2004;11:1540-8.
[43] Lee H, Koehler DR, Pang CY, Levine RH, Ng P, Palmer DJ, et al. Gene delivery to human
sweat glands: a model for cystic fibrosis gene therapy. Gene Ther 2005;12:1752-60.
[44] Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. Acute toxicity
after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman
primates. Hum Gene Ther 2004;15:35-46.
[45] Ng P, Beauchamp C, Evelegh C, Parks R, Graham FL. Development of a FLP/frt system
for generating helperdependent adenoviral vectors. Mol Ther 2001;3:809-15.
[46] Umana P, Gerdes CA, Stone D, Davis JR, Ward D, Castro MG, et al. Efficient FLPe
recombinase enables scalable production of helper-dependent adenoviral vectors with
negligible helper-virus contamination. Nat Biotechnol 2001;19:582-5.
[47] Guha C, Shah SJ, Ghosh SS, Lee SW, Roy Chowdhury N, Roy Chowdhury J. Molecular
therapies for viral hepatitis. Biodrugs 2003;17:81-91.
[48] Pastore L, Morral N, Zhou H, Garcia R, Parks RJ, Kochanek S. Use of a liver-specific
promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene
Ther 1999;10:1773-81.
[49] Sullivan DE, Dash S, Du H, Hiramatsu N, Aydin F, Kolls J, et al. Liver-directed gene
transfer in non-human primates. Hum Gene Ther 1997;8:1195-206.
[50] Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to
viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U.S.A.
1994;91:4407-11.
[51] Ghosh SS, Sappal BS, Kalpana GV, Lee SW, Chowdhury JR, Chowdhury NR.
Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltrans-
ferase-1 (UGT1A1) and its functional implications. J Biol Chem 2001;276(42):108-15.
[52] Greeve J, Jona VK, Chowdhury NR, Horwitz MS, Chowdhury JR. Hepatic gene transfer
of the catalytic subunit of the apolipoprotein B mRNA editing enzyme results in a reduc-
tion of plasma LDL levels in normal and Watanabe heritable hyperlipidemic rabbits.
J Lipid Res 1996;37:2001-17.
[53] Koizumi M, Doi R, Toyoda E. Hepatic regeneration and enforced PDX-1 expression
accelerate transdifferentiation in liver. Surgery 2004;136:449-57.
[54] Wadler S, Kaufman H, Horwitz M, Morley S, Kirn D, Brown R, et al. The dl1520 virus is
found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma.
Clin Cancer Res 2005;11(2781):2782.
[55] Warren RS, Kirn DH. Liver-directed viral therapy for cancer p53-targeted adenoviruses
and beyond. Surg Oncol Clin N Am 2002;11:571-88.